Jade Biosciences
JBIO
13.77
+0.36
+2.68%
Jade Biosciences
US · JBIO
#3338 by market cap
Listed 2021
13.77
+0.36
+2.68%
Live - 5344 symbols - heartbeat 303s ago
· 2026-10-08 08:46
Pre-market
13.30
-3.41%
After-hours
13.00
-5.59%
- Market cap
- 875.74M
- P/E (TTM)i
- -12.87
- P/Bi
- 1.99
- EPSi
- -3.19
- Div yieldi
- 0.00%
- 52W posi
- 28%
Reader sentiment
Are you bullish or bearish on JBIO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 0.3 percentage points.
Institutional ownership
- Held by institutions
- 115.51% +0.31pp
- Institutions
- 189
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund63.18%
Hedge Fund32.51%
VC/PE Fund16.75%
Public Company2.35%
Private Company0.43%
Individual/Insider0.28%
Government Pension Fund0.17%
Insurance Company0.11%
Top holders as of 2026-06-30
FMR
14.35% · 9.13M sh
Janus Henderson Group plc
9.86% · 6.27M sh
Fairmount Funds Management LLC
7.16% · 4.55M sh
RA Capital Management, L.P.
5.77% · 3.67M sh
VR Management, LLC
5.06% · 3.22M sh
Paradigm Biocapital Advisors LP
4.89% · 3.11M sh
Bellevue Asset Management AG
4.81% · 3.06M sh
BlackRock
4.40% · 2.80M sh
Franklin Resources
4.39% · 2.79M sh
Vanguard Capital Management, LLC
4.01% · 2.55M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
41 filings tracked · 23 buys · 6 sells
| Name | Role | Stake |
|---|---|---|
| Andrew King | Chief Scientific Officer & Head of R&D | 0.21% |
| Lawrence Klein | Director | 0.05% |
| Tom Frohlich | Chief Executive Officer | 0.01% |
| Eric Dobmeier | Chairperson | -- |
| Tomas Kiselak | Director | -- |
| Christopher Cain | Director | -- |
| Fairmount Funds Management LLC | -- | -- |
| Erin Lavelle | Director | -- |
| Fairmount Healthcare Fund II L.P. | -- | -- |
| Bradford Dahms | Chief Financial Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-24 | Mark Eisner | Director | Other Derivative Acquisition | +47,675 | $21.81 |
| 2026-06-08 | Eric Dobmeier | Chairperson | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-06-08 | Christopher Cain | Director | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-06-08 | Erin Lavelle | Director | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-06-08 | Lawrence Klein | Director | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-06-08 | Peter Harwin | -- | Other Derivative Acquisition | +34,843 | $15.22 |
| 2026-02-11 | Tom Frohlich | Chief Executive Officer | Other Acquisition | +78,750 | -- |
| 2026-02-11 | Tom Frohlich | Chief Executive Officer | Other Derivative Acquisition | +472,500 | $14.81 |
| 2026-02-11 | Bradford Dahms | Chief Financial Officer | Other Acquisition | +37,813 | -- |
| 2026-02-11 | Bradford Dahms | Chief Financial Officer | Other Derivative Acquisition | +226,875 | $14.81 |
| 2026-02-11 | Andrew King | Chief Scientific Officer & Head of R&D | Other Acquisition | +41,250 | -- |
| 2026-02-11 | Andrew King | Chief Scientific Officer & Head of R&D | Other Derivative Acquisition | +247,500 | $14.81 |
| 2026-02-11 | Elizabeth Bekiroglu | -- | Other Acquisition | +28,125 | -- |
| 2026-02-11 | Elizabeth Bekiroglu | -- | Other Derivative Acquisition | +168,750 | $14.81 |
| 2025-10-05 | Fairmount Funds Management LLC | -- | Private Acquisition | +1,333,126 | $9.14 |
| 2025-10-05 | Fairmount Funds Management LLC | -- | Other Derivative Acquisition | +855,047 | $0.00 |
| 2025-07-13 | Bradford Dahms | Chief Financial Officer | Other Derivative Acquisition | +526,000 | $9.00 |
| 2025-06-24 | Atlas Venture Advisors, Inc. | -- | Intent to Sell (Form 144) | -28,977 | $10.48 |
| 2025-06-24 | Atlas Venture Advisors, Inc. | -- | Intent to Sell (Form 144) | -235 | $10.48 |
| 2025-06-23 | Atlas Venture Advisors, Inc. | -- | Intent to Sell (Form 144) | -16,132 | $9.87 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:46:53 · For reference only, not investment advice and not tailored to your situation.